LXEO lexeotx.com: Enterprise Value to EBITDA Ratio
Lexeo Therapeutics (LXEO) is currently spending its existing reserves as planned to cover capital expenditures for medical product development. This price chart, featuring an EV/EBITDA ratio of 0.00, complements data regarding the firm's leadership in cardiac gene therapy, which ensures long-term revenue. While the company lacks pricing power, it is developing unique solutions for genetic profile modification in Alzheimer's disease.
LXEO (lexeotx.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital Lexeo Therapeutics|LXEO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Lexeo Therapeutics, Inc.|LXEO - Aggregate Debt Obligations|Debts to Book Capitalization Lexeo Therapeutics, Inc.|LXEO - Company Long-Term Debts|Company Short-Term Debt Lexeo Therapeutics|Quick Ratio lexeotx.com
- net income and valuation multiples indicators:
LXEO - Company Net Income|Future Profit Lexeo Therapeutics|LXEO - P/E Multiple|Projected Price to Earnings Lexeo Therapeutics, Inc.|LXEO - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Lexeo Therapeutics, Inc.|LXEO - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Lexeo Therapeutics|LXEO - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months lexeotx.com|LXEO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Lexeo Therapeutics
Summary company analysis:Lexeo LXEO
This indicator determines the business value relative to its operating profit before depreciation, taxes, and interest. The EV/EBITDA ratio dynamics, accounting for operating profit and depreciation, reflect the real value of assets net of debt. This metric measures the investment payback period by neutralizing the impact of tax regimes and credit structures. For Lexeo Therapeutics (LXEO), this is critical: following the expensive development phase, scalable drug synthesis sharply increases EBITDA, thereby lowering the multiple.
Competitors of Lexeo Therapeutics
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Qiagen Corp (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGEN (repligen.com)|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRSP: Enterprise Value to Operating Income Before Depreciation Ratio|WGS (Sema4) - EV/EBITDA Multiple|RARE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BEAM|SRPT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|Business Value to Operating Income Before Depreciation TXG|Intellia - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio WVE (wavelifesciences.com)|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA Sionna Therapeutics, Inc. SION|Enterprise Value to EBITDA Ratio PRME (Prime Medicine Corp)|EV/EBITDA Multiple Taysha Corp (TSHA)|uniQure N.V. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MGTX (meiragtx.com)|REGENXBIO - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Solid Biosciences Inc SLDB|OCGN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PacBio Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Benitec Biopharma Inc.|designtx.com (DSGN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rocket Pharmaceuticals, Inc. (RCKT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FDMT (4DMT)|Korro Bio - Enterprise Value to EBITDA Ratio|EDIT: Enterprise Value to Operating Income Before Depreciation|Silence Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA ProQR Therapeutics N.V.|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Sangamo Therapeutics Inc. (SGMO)|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation MGX (Metagenomi Therapeutics)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|generationbio.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio)|EV/EBITDA Multiple Exicure Inc. XCUR|IMNN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PHIO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MBIO: EV/EBITDA Multiple|Company Value to EBITDA TransCode Therapeutics, Inc. (RNAZ)|Enterprise Value to EBITDA Ratio BNGO|Enterprise Value to Operating Income Before Depreciation APDN (Applied DNA Sciences Inc)|EV/EBITDA Multiple BLUE|IPA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|singulargenomics.com (OMIC) - Company Value to EBITDA|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals Inc.)|TBIO (Codex DNA) - Enterprise Value to EBITDA Ratio|TCON: Enterprise Value to Operating Income Before Depreciation Ratio|UBX (Unity Biotechnology) - EV/EBITDA Multiple
